Catalyst Biosciences and members of its board were hit with a stockholder class action Thursday in Delaware Court of Chancery in connection with asset purchase and business combination agreements with GNI Group and Shanghai Genomics. The lawsuit, brought by Weiss Law and Bielli & Klauder, accuses the defendants of failing to disclose financial projections and related analyses for 2023 through 2031 and making other material omissions. Counsel have not yet appeared for the defendants. The case is 2023-0403, Stephen Bushansky v. Catalyst Biosciences, Inc.
Biotech & Pharmaceuticals
April 06, 2023, 3:02 PM